miR-155 在白血病患者中的预后作用：一项荟萃分析。

Prognostic role of microRNA-155 in patients with leukemia: A meta-analysis.

机构信息

Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan 250062, China.

Shandong Xinchuang Biotechnology Co., LTD, Jinan 250102, China.

出版信息

Clin Chim Acta. 2018 Aug;483:6-13. doi: 10.1016/j.cca.2018.04.015. Epub 2018 Apr 11.

DOI:10.1016/j.cca.2018.04.015

PMID:29654787

Abstract

BACKGROUND

Recent studies have shown that microRNA-155 (miR-155) is correlated with clinical outcomes of leukemia. This meta-analysis explores to evaluate the prognostic value of miR-155 for survival in patients with leukemia.

METHODS

Eligible studies were searched from PubMed and EMBASE databases. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for overall survival (OS), disease-free survival, event-free survival, progression-free survival and treatment-free survival were extracted, if available. Pooled HRs and 95% CIs were used to study any correlation between miR-155 and survival.

RESULTS

11 studies from 10 articles containing 1718 leukemia patients were included. Data showed that the pooled HR for OS was 1.67 (95% CI: 1.44-1.95, P < 0.01). Subgroup analyses for OS showed that the pooled HRs and their 95% CIs were 1.68, 1.41-2.00 (P < 0.01) and 1.73, 1.25-2.41 (P < 0.01) for acute myeloid leukemia and chronic lymphoblastic leukemia, respectively. Furthermore, there was no significant heterogeneity or publication bias among the enrolled datasets.

CONCLUSION

We conclude that high miR-155 expression was associated with shorter OS for leukemia patients, and that miR-155 might be a promising prognostic biomarker for this patient population.

摘要

背景

最近的研究表明，微小 RNA-155（miR-155）与白血病的临床结局相关。本荟萃分析旨在评估 miR-155 对白血病患者生存的预后价值。

方法

从 PubMed 和 EMBASE 数据库中搜索符合条件的研究。如果有可用数据，则提取总生存（OS）、无病生存、无事件生存、无进展生存和无治疗生存的风险比（HR）和相应的 95%置信区间（CI）。使用合并 HR 和 95%CI 来研究 miR-155 与生存之间的任何相关性。

结果

纳入的 10 篇文献中有 11 项研究，包含 1718 例白血病患者。结果显示，OS 的合并 HR 为 1.67（95%CI：1.44-1.95，P<0.01）。OS 的亚组分析显示，合并 HRs 及其 95%CI 分别为 1.68、1.41-2.00（P<0.01）和 1.73、1.25-2.41（P<0.01），分别用于急性髓系白血病和慢性淋巴细胞白血病。此外，纳入的数据集之间没有显著的异质性或发表偏倚。